KINDLIN3 Antibody
Code | Size | Price |
---|
PSI-4797-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-4797-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
KINDLIN3 Antibody: URP2, KIND3, MIG-2, MIG2B, URP2SF, UNC112C, URP2, Fermitin family homolog 3, Kindlin-3
Application Note:
KINDLIN3 antibody can be used for detection of KINDLIN3 by Western blot at 1 and 2 μg/mL.
Antibody validated: Western Blot in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples. All other applications and species not yet tested.
Background:
KINDLIN3 Antibody: The three KINDLINs are a novel family of focal adhesion proteins, localizing to integrin adhesion sites. The KINDLIN proteins are composed of a centrally located FERM domain interrupted by a pleckstrin homology (PH) domain. KINDLIN1 and KINDLIN2 have been shown to play an essential role in integrin-mediated adhesion and spreading. In contrast to the widely expressed KINDLIN1 and KINDLIN2, KINDLIN3 is restricted to hematopoietic cells and is particularly abundant in megakaryocytes and platelets. Several reports describe a transcriptional misregulation of KINDLINs in various types of cancer. A recent study demonstrates that KINDLIN3 is essential for platelet integrin activation and subsequent integrin outside-in signaling, suggesting it may serve as a potential target for the design of therapeutics aimed at specifically disrupting integrin activation in platelets and leukocytes.
Background References:
- Ussar S, Wang HV, Linder S, et al. The Kindlins: subcellular localization and expression during murine development. Exp. Cell Res.2006; 312:3142-51.
- Weinstein EJ, Bourner M, Head R, et al. URP1: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas. Biochim. Biophys. Acta2003; 1637:207-16.
- Boyd RS, Adam PJ, Patel S, et al. Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B. Leukemia2003; 17:1605-12.
- Mory A, Feigelson SW, Yarali N, et al. Kindlin-3: a new gene involved in the pathogenesis of LAD-III. Blood2008; 112:2591.
Buffer:
KINDLIN3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%)
Immunogen:
KINDLIN3 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of the human KINDLIN3.
The immunogen is located within the last 50 amino acids of KINDLIN3.
The immunogen is located within the last 50 amino acids of KINDLIN3.
NCBI Gene ID #:
83706
NCBI Official Name:
fermitin family homolog 3 (Drosophila)
NCBI Official Symbol:
FERMT3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 73 kDa
Observed: 73 kDa
Observed: 73 kDa
Protein Accession #:
NP_848537
Protein GI Number:
41281905
Purification:
KINDLIN3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
Swissprot #:
Q86UX7
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | KINDLIN3 Peptide | PSI-4797P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|